AstraZeneca Covid-19 vaccine 76pct effective in new analysis of US trial


25 Mac 2021, 5:04 pagi

Updated 3 months ago


AstraZeneca said its Covid-19 vaccine was 76 percent effective at preventing symptomatic illness in a new analysis of its major US trial - a tad lower than the level announced earlier this week in a report that was criticised for using outdated information.

US health officials had publicly rebuked the drugmaker for not using the most up-to-date information when it published an interim analysis on Monday that said the vaccine was 79 percent effective...

All Access Plan


per month
Unlimited access to our articles
Comment on all our stories
Gift articles to your friends
Subscribe Now
You can cancel anytime.
Secure and Encrypted
Student or Senior Citizen? Get a special rateGroup / Institutional / Corporate Plans
Already Subscribed?
Sign In

View Comments (0)